Nitisinone

證據等級: L5

預測適應症: 10 個

Nitisinone: From Hereditary Tyrosinemia Type 1 to Renal Tubular Acidosis

One-Sentence Summary

Nitisinone (NTBC) was originally developed to treat hereditary tyrosinemia type 1 (HT-1), a rare inherited metabolic disorder, by blocking the enzyme that generates toxic tyrosine-degradation byproducts. The TxGNN model predicts it may also be effective for Renal Tubular Acidosis, a known renal complication of untreated HT-1, with 0 clinical trials but 2 supporting publications (a cohort study and a case series) currently available.

Quick Overview

Item	Content
Original Indication	Hereditary Tyrosinemia Type 1 (HT-1) (inferred from repurposing rationale text; no formal license record exists — drug is not marketed in Norway)
Predicted New Indication	Renal Tubular Acidosis
TxGNN Prediction Score	99.96%
Evidence Level	L3
Norway Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

The formal mechanism-of-action field for nitisinone is currently a data gap in this evidence pack. However, the repurposing rationale attached to this prediction indicates that nitisinone (NTBC) acts by inhibiting 4-hydroxyphenylpyruvate dioxygenase (HPPD), an enzyme upstream in the tyrosine degradation pathway. By blocking this enzyme, nitisinone prevents the formation of toxic downstream metabolites — most notably succinylacetone — which are responsible for the liver and kidney damage seen in HT-1.

Renal tubular acidosis and broader proximal renal tubular dysfunction are well-recognized complications of untreated or inadequately treated HT-1, arising directly from succinylacetone-mediated toxicity to the proximal tubule. Because nitisinone's original approved use already targets the root metabolic defect that causes this renal damage, the predicted new indication is not a novel mechanistic extrapolation — it represents treatment of a downstream complication of the drug's own original indication.

This gives the prediction a comparatively high degree of mechanistic plausibility relative to other TxGNN outputs for this drug: the pathway linking cause (toxic metabolite accumulation) and effect (tubular injury) is already established in the HT-1 literature, and nitisinone's core pharmacology (HPPD inhibition) directly addresses that cause.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
25172236	2014	Cohort	Molecular Genetics and Metabolism	Describes the early effect of NTBC on renal tubular dysfunction in patients with hereditary tyrosinemia type 1, finding that NTBC therapy is associated with improvement in tubular function markers.
27109516	2016	Case Series	Indian Journal of Gastroenterology	Case series of four children with tyrosinemia type 1 treated with NTBC; three of four showed sustained normal liver function and undetectable urine succinylacetone over ~3 years of therapy, consistent with reduced tubular toxin burden.

Norway Market Information

Nitisinone currently holds no marketing authorization in Norway (market status: not marketed; 0 authorizations on record), so no product/authorization table is available.

Safety Considerations

Please refer to the package insert for safety information.

(Note: Key warnings, contraindications, and drug interaction data are currently marked as data gaps in this evidence pack — notably, TFDA package insert retrieval (DG001) is flagged as a Blocking severity gap that must be resolved before any formal safety assessment (S1 stage) can proceed.)

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The mechanistic link between nitisinone's established pharmacology (HPPD inhibition, blocking toxic tyrosine-pathway metabolites) and renal tubular acidosis as a downstream HT-1 complication is biologically coherent and supported by two independent publications (a cohort study and a case series) showing renal tubular improvement with NTBC treatment. However, no dedicated clinical trials have directly tested nitisinone for this indication, and evidence remains observational (L3).

To proceed, the following is needed:

TFDA/package insert data on warnings and contraindications (currently a Blocking data gap — DG001) to complete the S1 safety pre-assessment
Formal mechanism-of-action documentation from DrugBank (data gap — DG002) to confirm and strengthen the mechanistic rationale
Prospective or controlled studies specifically evaluating renal tubular function as a primary outcome in NTBC-treated HT-1 patients
Norway-specific regulatory pathway assessment, given the drug currently holds no marketing authorization there
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.